Work

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.2504

Authors: Daniel A. Vaena, Gini F. Fleming, Bartosz Chmielowski, Manish Sharma, Erika P. Hamilton, Ryan J. Sullivan, Dale Randall Shepard, Kyriakos P. Papadopoulos, Amita Patnaik, Adam ElNaggar, Adeboye H. Adewoye, Robina Smith, Emerson A. Lim, Ecaterina Elena Dumbrava, Drew W. Rasco

Institutions: University of Chicago, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Tennessee Oncology, Massachusetts General Hospital, Cleveland Clinic, South Texas Accelerated Research Therapeutics, West Cancer Center, Herbert Irving Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3170708911

Cites:

Cited by: 14

Related to: 10